Bacterial Vaginosis (BV) is one of the most common diseases in women. Traditional treatment primarily target female patients, but the high recurrence rate has remained a significant challenge. A groundbreaking study published in the New England Journal of Medicine has brought a breakthrough in this area: treating male partners can significantly reduce the recurrence rate of BV in women. This discovery not only changes the treatment paradigm for BV but also provides a new direction for new drug development.

Bacterial Vaginosis is an infection caused by an imbalance in the vaginal microbiota, with symptoms including unusual odor, abnormal discharge, and, in severe cases, complications such as pelvic inflammatory disease, infertility, and even preterm birth. Currently, the standard treatment for BV involves antibiotics (such as metronidazole or clindamycin), but up to 50% of patients experience a recurrence within six months after treatment. This high recurrence rate not only affects patients' quality of life but also places a heavy burden on healthcare systems. The study published in the New England Journal of Medicine is the first to suggest that BV may be transmitted through sexual activity, and male partners could be a potential source of recurrent infections in female patients. The study shows that when male partners are treated simultaneously, the recurrence rate in female patients is significantly reduced. This finding overturns traditional views, emphasizes the importance of partner-inclusive treatment, and offers a novel approach to the prevention and management of BV.

As a new drug development company in infectious disease area, TenNor has been committed to addressing unmet clinical needs in disease areas associated with bacterial infections and bacterial metabolism. On May 28, 2024, International Day of Action for Women's Health, the Journal of Medicinal Chemistry of the American Chemical Society published a special issue featuring 17 research articles focused on unmet clinical needs in women's health. TenNor's article on the use of TNP-2198 (rifasutenizol) for treating microaerophilic and anaerobic bacterial infections was included in this special issue, recognizing its contribution to advancing research in women's health.

For more details, visit: https://www.nationalgeographic.com/health/article/bacterial-vaginosis-sexually-transmitted.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com